According to Future Market Insights' recently published global research antibodies market analysis report, the current valuation of the global market is USD 4.1 Billion, which is projected to increase by 7.3% to reach USD 4.3 Billion market by the end of 2022.
According to the report, the worldwide revenue of the research antibodies market is anticipated to increase at an 8.1% CAGR during the timeframe. The expected market growth rate is significantly higher than the historical rate of 6.8% from 2017 to 2021. In the next ten years, the market valuation will reach USD 9.6 Billion, with an absolute dollar opportunity of USD 5.2 Billion. The research antibodies market’s growth is attributed to the below-mentioned reasons:
The COVID-19 epidemic has generated extensive pharmaceutical behemoths with lucrative growth opportunities, with multiple pharmaceutical behemoths investing heavily in R&D to create novel vaccines, therapeutic approaches, and diagnostic devices. These concise R&D operations throughout the business have a significant influence on the global consumption of research antibodies.
Biosolutions, for example, is operating with the USA government to devise a plasma-derived therapy for Covid-19 patients. The government awarded the company with D14.5 million to conduct antibody-drug trials. As a result, stringent development of medicines and vaccines has been incentivized throughout this time, leading to an increase in global growth for Research Antibodies.
| Attributes | Details |
|---|---|
| Research Antibodies Market CAGR (2022 to 2032) | 8.1% |
| Research Antibodies Market Size (2022) | USD 4.4 Billion |
| Research Antibodies Market Size (2032) | USD 9.6 Billion |
With the aging populace added to the increasing prevalence of neurodegenerative diseases, the limited success of preventative treatments, the attractiveness of advancing healthcare services, and greater funding for genomic research, the demand for biographical antibodies has seen a tremendous upsurge recently.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The market in the United States is expected to expand at an 8.3% CAGR between 2022 and 2032. This developmental rate is significantly higher than the historical rate of 6.5% from 2017 to 2021. In the next ten years, the USA market is anticipated to support the largest absolute dollar opportunity of USD 1.5 Billion.
The growing emphasis on biomedical, stem cell, and cancer research has been a major factor contributing to the substantial market in the United States. The increased incidence of cardiovascular and blood diseases is likely to contribute to its growth.
The growing acceptance and utilization of Research Antibodies have generated a competitive environment among industry stakeholders.
Furthermore, the fundamental approaches of huge companies such as mergers, partnerships, and acquisitions are expected to increase sales volume and intensify competition. To uphold their dominant position, the industry leaders are working to develop cost-effective antibodies by investing heavily in R&D.
Abcam Plc, Agilent Technologies, Bio-rad Laboratories, Becton Dickinson & Company, Cell Signalling Technology, Inc., F. Hoffmann La Roche Ltd., Lonza Group, Merck Millipore, Perkinelmer Inc., and Thermo Fisher Scientific, Inc. are the key players in the market in the Research Antibodies Market.
With the aging populace added to the increasing prevalence of neurodegenerative diseases, the limited success of preventative treatments, the attractiveness of advancing healthcare services, and greater funding for genomic research, the demand for biographical antibodies has seen a tremendous upsurge recently.
Principal Consultant
As per the Research Antibodies Market report published by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market of Research Antibodies grew at a CAGR of 6.6% while the projected growth stands at a CAGR of 8.1% during the period between 2022 and 2032.
The global market is valued at USD 4.4 Billion in 2022 and is expected to reach the valuation of USD 9.6 Billion by the end of 2032. USA is likely to dominate the market for Research Antibodies with nearly 29% stake in the global market rising at a CAGR of 8.3% during the period between 2022 and 2032. The market in Japan and China is expected to grow at the highest CAGR of 10.8% and 10.6% respectively during 2022 to 2032.
Western Blotting segment leads the global market for Regenerative Antibodies by growing at a CAGR of 7.6% during 2022 to 2032.
The rising prevalence of neurodegenerative illnesses, the ageing population, the lack of viable treatments, and increased funding for genomics research have all contributed to a significant increase in demand for research antibodies.
The rising prevalence of neurodegenerative disorders like Huntington's disease, Multiple Sclerosis, and Parkinson's disease is spurring neurobiology research market.
Due to a dearth of alternative therapy choices, research antibodies are in high demand to create personalised medicines, improved therapies, and effective treatments. With the onset of pandemic, the global pharmaceutical giants got an option to invest heavily in R&D to produce novel vaccines, treatment techniques, and diagnostic kits.
Another factor expected to enhance market expansion is increased funding supplied by government entities and private companies for proteomics and genomics research. With the help of genomic technologies, the scientists were able to identify the root causes of death.
Emerging markets are projected to provide new growth prospects for large research antibody makers. Growth in the biopharmaceutical industry, as well as rising R&D spending in emerging regions, could lead to new opportunities in the research antibody market.
Rising cases of cancer have significantly pushed the demand for research antibodies. As a result of increased investment in stem cells related research activities, the market for Research Antibodies surged.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The USA dominates the global market for Research Antibodies with a significant market share of around 29% in 2029.
This market is expected to increase at a projected CAGR of 8.3% during the period between 2022 and 2032. This growth is significantly higher than the historical growth of just 6.5% during 2017-2021. The USA market is expected to offer the largest absolute dollar opportunity of USD 1.5 Billion in the next 10 years.
A growing emphasis on biomedical, stem cell and cancer research is a key contributor to the large market in USA Its growth is likely to be fuelled by the increased prevalence of cardiovascular and blood diseases. As per the American Cancer Society Report, in the United States, approximately 1.8 Million new cancer cases were diagnosed and 606,520 new deaths were reported. These stats amplify the need for cancer and stem cell research which leads to an increased adoption rate of modern research antibodies products.
The USA is the largest contributor in the global Research Antibodies market with an absolute dollar opportunity of USD 1.5 Billion in the upcoming 10 years. Furthermore, Japan and China are leading the market in terms of high CAGR of 10.8% and 10.6% respectively for the period between 2022 and 2032.
Western Blotting segment leads the global market share with the majority stake growing at a CAGR of 8.8% during the forecast period. This segment is expected to grow significantly as compared to its historic CAGR of just 6.5%. This technology is widely used due to the rising prevalence of disorders with limited treatment alternatives.
Due to the increased precision afforded by the western blotting technique, it is increasingly being favoured over all the other technologies for diagnosing HIV antibodies including ELISA testing and flow cytometry.
The Primary product segment is the largest contributor to the global Research Antibodies Market with an expected CAGR of 8.4% during the period between 2022 and 2032. This growth has been significantly higher than the historical growth of 7.1%.
The increasing acceptance and implementation of Research Antibodies has created a competitive environment among industry players. Furthermore, the large corporations' fundamental strategies of mergers, partnerships, and acquisitions are expected to expand market share and intensify competition. In order to maintain their dominant position, the leading firms are working on building cost-effective antibodies by investing highly in R&D domain.
The key competitors in Research Antibodies Market are Abcam Plc, Agilent Technologies, Bio-rad Laboratories, Becton Dickinson & Company, Cell Signalling Technology, Inc., F. Hoffmann La Roche Ltd., Lonza Group, Merck Millipore, Perkinelmer Inc., and Thermo Fisher Scientific, Inc.
Some of the key developments in the Global research Antibodies Market being channelized by market players are as follows:
Similarly, recent developments related to companies offering Research Antibodies have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2032 |
| Historical Data | 2017 to 2021 |
| Quantitative Units | In USD Billion |
| Key Regions Covered | North America; Latin America; Europe; APAC and MEA |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Spain, Italy, Russia, China, Japan, India, South Korea, Australia, South Africa, Saudi Arabia, UAE, Israel |
| Key Market Segments Covered | Product Type and Region |
| Key Companies Profiled | Abcam Plc; Agilent Technologies; Bio-rad Laboratories; Becton Dickinson & Company; Cell Signalling Technology, Inc.; F. Hoffmann La Roche Ltd.; Lonza Group; Merck Millipore; Perkinelmer Inc.; Thermo Fisher Scientific, Inc. |
| Pricing | Available upon Request |
The Global Research Antibodies Market is currently worth more than USD 4.1 Billion and is expected to reach the valuation of USD 4.4 Billion by the end of 2022.
The Global Research Antibodies Market is expected to grow at a CAGR of 8.1% during the period between 2022 and 2032.
During the period between 2022 and 2032, the Global Market for Research Antibodies is likely to register an absolute dollar opportunity of USD 5.2 Billion. With this, the global market will be valued at USD 9.6 Billion by the end of 2032.
The Global Market for Research Antibodies is driven by the Primary product which is expected to grow at a CAGR of 8.3% during the period between 2022 and 2032.
The USA market is driving the global market for Research Antibodies with a dominant share of 29.5% in the global market. It is expected to grow at a CAGR of 8.3% during the period between 2022 and 2032 and provide an absolute dollar opportunity of USD 1.5 Billion in the upcoming 10 years.
The USA dominates the Global Market for Research Antibodies with around 29% share.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2017 to 2021 and Forecast, 2022 to 2032 5. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Product Type 5.1. Primary 5.2. Secondary 6. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Type 6.1. Monoclonal Antibodies 6.2. Polyclonal Antibodies 7. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Technology 7.1. Immunohistochemistry 7.2. Immunofluorescence 7.3. Western Blotting 7.4. Flow Cytometry 7.5. Immunoprecipitation 7.6. ELISA 7.7. Other Technologies 8. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Source 8.1. Mouse 8.2. Rabbit 8.3. Goat 8.4. Other Sources 9. Global Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Region 9.1. North America 9.2. Latin America 9.3. Europe 9.4. Asia Pacific 9.5. MEA 10. North America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 11. Latin America Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 12. Europe Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 13. Asia Pacific Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 14. MEA Market Analysis 2017 to 2021 and Forecast 2022 to 2032, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Abcam Plc 17.2. Agilent Technologies 17.3. Bio to rad Laboratories 17.4. Becton Dickinson & Company 17.5. Cell Signalling Technology, Inc. 17.6. F. Hoffman La Roche Ltd. 17.7. Lonza Group 17.8. Merck Millipore 17.9. PerkinElmer Inc. 17.10. Thermo Fisher Scientific, Inc. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Research Antibodies Market
